



TSXV: ADK  
For immediate distribution  
Source: DIAGNOS inc.

**2011.04.14**

## DIAGNOS to supply its CARA technology to Ophthalmolaser in Mexico and resignation of one Director

Brossard, Quebec, Canada – April 14<sup>th</sup>, 2011 – DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today that it has partnered with its distributor CANAMEXPORT SA de CV (Canamexport), to supply its CARA technology to OFTALMOLASER DE MEXICO S.A. DE C.V. (Oftalmolaser), the medical subsidiary of GRUPO DEVLYN, S.A. de C.V. (Devlyn). This achievement comes after the receipt of a Letter of Intent from Oftalmolaser (dated December 1<sup>st</sup>, 2010), and the Memorandum of Understanding (dated February 4<sup>th</sup>, 2010). Devlyn is the largest optical chain in Latin America with over 700 optical outlets and 7 ophthalmic clinics.

DIAGNOS, Canamexport and Oftalmolaser will work together to implement DIAGNOS' Computer Assisted Retinal Analysis (CARA) technology in Oftalmolaser medical clinics and Devlyn optical outlets. For a fee of US\$ 25 per patient, the CARA services will include automated image processing (enhancement and analysis), as well as professional grading.

“Grupo Devlyn’s leadership in providing ophthalmology services and their commitment to community service, including screening and blindness prevention, make them an ideal partner for DIAGNOS’ CARA technology, and we are very pleased to be continuing to grow the delivery of ophthalmology services in Latin America with Grupo Devlyn. We have been working together for several months with Grupo Devlyn, and with our Mexican partner Canamexport, and expect a smooth stage-gated expansion of our business together”, said Peter Nowacki, DIAGNOS’ Vice-President - Healthcare.

“Given our commitment as a family and as a business to the health of our communities, we plan to roll out CARA to support our screening for eye diseases at our chain of optical stores, to increase the rate and quality of referrals for treatment in our medical clinics, and ultimately to make a difference in the vision care of 15 million Mexicans with diabetes, 50% of whom are undiagnosed. We plan to scale-up to about a dozen optical stores in the 2011 fiscal year and look forward to working with DIAGNOS”, said Andrew Devlyn, Grupo Devlyn’s Medical Division Director.

DIAGNOS would also like to announce the resignation of Mr. Chris Orchard as a member of the Board of Director. We appreciated its dedication to the growth of DIAGNOS and would like to sincerely thank him for its contribution. Mr. Orchard is a Director at Anglo Pacific, a large shareholder of DIAGNOS. “Due to the current economic turnaround of the mining industry we, Anglo Pacific, have decided it is no longer required to be present on the Board of Director. I have enjoyed working with the Board this past two and a half years. We wish DIAGNOS well and continue to support the management team”, said Chris Orchard, Director & Chief Investment Officer, Anglo Pacific Group Plc.

### About Oftalmolaser

Oftalmolaser is a subsidiary of Grupo Devlyn and is a major provider of ophthalmic medical services, including surgical, services to its clients. Oftalmolaser currently operates 7 medical clinics in Mexico, and is growing its business throughout the region.

### About Devlyn

Founded in 1963, Grupo Devlyn is private company that operates a retail chain of over 700 optical stores in Mexico, Central America and California, and is the largest optical chain in Latin America.



*For immediate distribution*  
Source: DIAGNOS inc.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX: ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision-making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at [www.diagnos.com](http://www.diagnos.com) or the SEDAR website at [www.sedar.com](http://www.sedar.com). You may also contact our investor relations representative:

André Larente, President and CEO  
Telephone: 1-877-678-8882 or (450) 678-8882, ext. 224  
[alarente@diagnos.com](mailto:alarente@diagnos.com)